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Abstract
The treatment for patients with metastatic colorectal cancer has progressively 
improved over the past few decades with the development of more effective anti- 
cancer drugs and multi-disciplinary management approaches that combine sequential 
lines of non-cross-resistant drugs and increased use of potentially curative surgery 
for metastases of the liver and lung. In this setting, the introduction of monoclonal 
antibody therapies that target the epidermal growth factor receptor (EGFR) (cetux-
imab and panitumumab) has made an important contribution to improved patient 
outcomes. However, the efficacy of therapies is generally limited to a small proportion 
of patients and associated with toxicity and high cost. There is an urgent clinical need 
for robust predictive biomarkers to guide the effective use of therapy options. In 
this chapter we review clinical and molecular predictive markers of primary therapy 
response for metastatic colorectal cancer, focusing on anti-EGFR antibody therapies, 
discussing both currently approved and emerging biomarkers.
Keywords: metastatic colorectal cancer, epidermal growth factor receptor (EGFR), 
cetuximab, panitumumab, predictive biomarkers
1. Introduction
Metastatic colorectal cancer (mCRC) remains a major contributor to cancer-
related morbidity and mortality worldwide. Among patients diagnosed with 
colorectal cancer, approximately 20–25% present with distant metastases, while 
another 20–35% develop metastases following curative-intent treatment for early-
stage cancer [1]. The median overall survival for mCRC has improved significantly 
over the past few decades, increasing from 10 to 12 months for 5-fluorouracil plus 
leucovorin to currently beyond 30 months [2]. Improvements have been driven by 
advancements in surgery for metastatic disease, the expansion of chemotherapy 
options and the introduction of targeted therapies such as monoclonal antibodies 
against the epidermal growth factor receptor (EGFR) or the vascular endothelial 
growth factor A (VEGFA) [2]. Presently, there are 11 therapeutics approved by the 
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United States Food and Drug Administration (FDA) for the treatment of mCRC, 
including 5-fluorouracil, irinotecan, capecitabine, oxaliplatin, bevacizumab, cetux-
imab, panitumumab, ziv-aflibercept, regorafenib, ramucirumab, and trifluridine-
tipiracil. The expansion of treatment options has resulted in an increased clinical 
need for predictive biomarkers to guide the effective use of therapy. Only a small 
proportion of patients will respond to any given therapy, and treatments are associ-
ated with significant toxicities and often with high financial costs.
Predictive biomarkers for anti-cancer agents are best developed prospectively as 
companion diagnostics during the drug development process. However, these can 
also be developed retrospectively through analysis of samples and data from previ-
ously conducted randomized clinical trials. Another avenue for marker discovery 
are longitudinal studies of patients analyzing the emergence of drug resistant tumor 
clones, although mechanisms of intrinsic (primary) and acquired (secondary) 
drug resistance may differ. Predictive markers can provide either drug sensitivity 
(positive prediction of response) or resistance (negative prediction of response) 
information depending on the biomarker-drug relationship.
There are many challenges in the biomarker development process, such as 
the choice of analyte (e.g. urine, blood, tissue), cancer sampling procedures (e.g. 
circulating tumor cells, primary cancer, metastatic lesions), technology for marker 
evaluation (e.g. DNA, RNA or protein) and determination of clinically relevant 
cut-offs. In this chapter, we review development efforts for predictive biomarkers 
for patients with mCRC focusing on anti-EGFR antibody therapies. Our discussion 
will concentrate on markers of primary drug resistance; markers of acquired drug 
resistance have been summarized in recent reviews [3, 4].
2. Anti-EGFR therapy
EGFR is a tyrosine kinase transmembrane receptor that belongs to the ErbB 
protein family. EGFR-mediated signaling has important roles in cell proliferation, 
survival and differentiation, and dysregulation is a central driver in multiple malig-
nancies including colorectal cancer [4–6]. EGFR interacts with multiple ligands 
including epidermal growth factor (EGF), transforming growth factor alpha 
(TGF-α), amphiregulin (AREG), epiregulin (EPR), betacellulin (BTC), heparin-
binding EGF (HB-EGF), epigen (EPN), and neuregulin 1-4 (NRG1-4). Activation 
of EGFR following ligand binding triggers a variety of signaling cascades, including 
the RAS/MAPK, PI3K/AKT, PLCγ/PKC, SRC tyrosine kinase and STAT pathways. 
In addition, ligand binding can induce EGFR translocation to the nucleus where 
EGFR behaves as a co-transcriptional activator regulating key genes such as Aurora 
Kinase A (AURKA), Cyclin D1 (CCND1), Prostaglandin-Endoperoxide Synthase 2 
(PTGS2) and MYB Proto-Oncogene Like 2 (MYBL2).
EGFR is overexpressed in colorectal tumors, with most estimates between 40% 
and 80% depending on the methods and cut-offs used, highlighting the receptor 
as a prime drug target in this malignancy [7, 8]. Two monoclonal antibodies tar-
geting EGFR have been clinically approved for the treatment of mCRC including 
cetuximab (Erbitux®), a chimeric mouse-human IgG1 antibody, and panitumumab 
(Vectibix®), a humanized IgG2 antibody. Both antibodies bind the extracellular 
domain of EGFR, inhibiting ligand-induced tyrosine kinase activation and leading 
to EGFR cellular internalization and degradation, thereby preventing the activation 
of downstream signaling (Figure 1). Panitumumab has a higher binding affinity for 
EGFR than cetuximab [9], and cetuximab is thought to additionally lead to activa-
tion of the immune response through antibody-dependent cell-mediated cytotoxic-
ity (ADCC) due to the IgG1 chimeric antibody structure [10, 11]. With respect to 
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toxicity, panitumumab treatment is associated with significantly lower occurrence 
of grade 3–4 infusion reactions (allergic reactions) than cetuximab due to its fully 
humanized nature [12]. Despite these differences, cetuximab and panitumumab 
showed clinical equivalence in efficacy in refractory patients [12], and both are 
approved for use in combination with chemotherapy in the first and second line 
setting or as monotherapy for refractory disease.
In unselected patient populations, the response rate to anti-EGFR therapy is 
typically less than 30% [13], and for patients who initially respond to treatment most 
tumors become refractory within 3–12 months [14]. The need to identify biomarkers 
predictive of EGFR response is therefore vital, and numerous studies have explored 
resistance mechanisms to EGFR blockade. Findings have unraveled a variety of 
biomarkers and pathways that are associated with resistance to anti-EGFR therapy. 
As discussed below, this work has led to the endorsement of predictive testing for 
tumor RAS (KRAS and NRAS) mutation status and consideration of primary tumor 
location to guide the use of anti-EGFR therapy. Efforts to discover and validate 
additional biomarkers is ongoing to further refine treatment delivery are ongoing.
2.1 Current predictive biomarkers for anti-EGFR therapy
2.1.1 KRAS and NRAS mutations
Genes of the RAS type GTPase family, comprising KRAS, NRAS and HRAS, are 
principal downstream mediators of activated EGFR signaling [15]. In colorectal 
cancer, KRAS and NRAS are major oncogenes, with activating mutations found in 
approximately 40% and 3–5% of cases, respectively [16]. Constitutive downstream 
signaling through oncogenic RAS proteins activates processes contributing to tumor 
progression and metastasis, independent of EGFR and other cell surface receptor 
Figure 1. 
Targeting of the EGFR signaling pathway with anti-EGFR monoclonal antibodies. EGFR activation is triggered by 
ligand binding which results in the formation of receptor homo- or hetero-dimers. Receptor autophosphorylation 
at tyrosine residues within the cytoplasmic tail acts as a docking site for proteins with Src homology2 (SH2) and 
phosphotyrosine-binding domains (PTB), initiating cellular signaling via the RAS/MAPK, PI3K/AKT, STAT and 
PLCγ/PKC pathways. Ligand binding can further stimulate EGFR translocation into the nucleus, with nuclear 
EGFR interacting with transcription factors to drive expression of target genes including NOS2, PTGS2, AURKA, 
MYBL2 and CCND1. EGFR signaling in tumor cells promotes cell proliferation and survival, and this can be 
blocked with antibodies against the receptor (cetuximab and panitumumab).
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kinases [15]. As anticipated from the biological mechanism, mutations in KRAS and 
NRAS genes have been found to render tumors insensitive to anti-EGFR therapy.
The majority of KRAS mutations (85–90%) in colorectal cancer occur in exon 2 
at codons 12 and 13 [16]. Analyses of clinical trials of cetuximab or panitumumab 
over the last decade have provided conclusive evidence that patients with KRAS 
mutations in exon 2 do not benefit from anti-EGFR therapy when given as a single 
agent or combined with chemotherapy (Table 1) [17–24]. Retrospective analyses of 
the randomized phase III CO.17 and 20020408 studies which evaluated cetuximab 
or panitumumab plus best supportive care (BSC) vs BSC alone in patients with 
chemotherapy-refractory mCRC, respectively, found a significant improvement in 
outcomes for patients with wild-type KRAS exon 2 tumors, but no benefit of anti-
EGFR therapy in patients who had mutant KRAS exon 2 tumors [19, 22]. Similar 
results for the first-line setting were subsequently reported for both retrospective 
and prospective analyses of several randomized clinical trials, including the phase 
II OPUS and phase III PRIME studies which examined cetuximab or panitumumab 
plus oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) vs FOLFOX4 alone, 
respectively [23, 25], and the phase III CRYSTAL study which assessed the addition 
of cetuximab to irinotecan, infusional fluorouracil, and leucovorin (FOLFIRI) [18]. 
Prospective analysis of the randomized phase III 20050181 study which evaluated 
panitumumab plus FOLFIRI in the second-line setting further confirmed the 
predictive value of KRAS exon 2 mutation status [24].
There is evidence that KRAS codon 12 and 13 mutations may exhibit differential 
biological effects, including variable ratios of these codon mutations between tumor 
types [16] and weaker in vitro transforming activity for KRAS codon 13 as compared 
to codon 12 mutant proteins [26]. Accordingly, some studies have suggested that 
patients with KRAS glycine (G)-to-aspartate (D) transitions at codon 13 (G13D), the 
most common codon 13 variant in colorectal cancer, might derive some benefit from 
anti-EGFR therapy [27, 28]. A retrospective consortium analysis assessing patients 
with chemotherapy-refractory mCRC treated with cetuximab who participated in 
multiple clinical trials (CO.17, BOND, MABEL, EMR202600, EVEREST, BABEL and 
SALVAGE) or who received off-study treatment reported longer overall and progres-
sion-free survival among individuals with KRAS G13D-mutated tumors than with 
other KRAS-mutated tumors [27]. An analysis of the updated pooled data sets from 
the CRYSTAL and OPUS studies also reported that addition of cetuximab to first-line 
chemotherapy appeared to benefit patients with KRAS G13D-mutant tumors [28]. In 
contrast, a retrospective analysis of 110 patients treated with cetuximab, found that 
patients with KRAS G13D mutations were unlikely to respond to therapy [29], and 
similar findings were reported for a retrospective pooled analysis of three randomized 
phase III trials evaluating panitumumab therapy (20050203, first line; 20050181, 
second line; and 20020408, monotherapy) [30]. To resolve this controversy, the ran-
domized phase II ICECREAM study prospectively assessed cetuximab monotherapy 
and cetuximab plus irinotecan in patients with KRAS G13D-mutated chemotherapy-
refractory mCRC. In this study, no statistically significant improvement in disease 
control was observed for patients with this rare molecular subtype [31].
More recently, several retrospective analyses have indicated that not only KRAS 
exon 2 mutations but also KRAS exons 3 and 4 and NRAS exons 2, 3, and 4 muta-
tions are negative predictive markers for anti-EGFR therapy [23, 32–36]. These 
additional mutations are observed in approximately 15–20% of wild-type KRAS 
exon 2 tumors [23, 32]. Reassessment of the randomized OPUS and PRIME studies 
of cetuximab or panitumumab plus FOLFOX4 vs FOLFOX4 alone in the first-line 
setting found that additional RAS mutations predicted a lack of response [23, 34], 
and corresponding observations were reported for the CRYSTAL study of cetuximab 
plus FOLFIRI [32]. Accordingly, analyses of single arms of the phase III FIRE-3 study 
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evaluating cetuximab plus FOLFIRI and the phase II PEAK study evaluating panitu-
mumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) in the 
first-line setting reported a more pronounced survival advantage for the wild-type 
RAS population as compared to the wild-type KRAS exon 2 population [36, 37]. 
Retrospective analysis of the randomized 20050181 study of panitumumab plus 
Study Treatment 
arms
Number of 
patients
PFS 
(months)
HR 
PFS
95% CI p-Value
RAS wild-type
CRYSTAL FOLFIRI + C 178 11.4 0.56 0.41–
0.76
p < 0.001
FOLFIRI 189 8.4
FIRE-3 FOLFIRI + C 199 10.3 0.97 0.88–
1.99
0.77
FOLFIRI +B 201 10.2
OPUS FOLFOX + C 38 12 0.53 0.27–
1.04
0.0615
FOLFOX 49 5.8
PEAK FOLFOX + P 50 13 0.65 0.44–
0.96
0.029
FOLFOX + B 60 9.5
PRIME FOLFOX + P 259 10.1 0.72 0.58–
0.90
0.004
FOLFOX 253 7.9
20050181 FOLFIRI + P 208 6.4 0.7 0.54–
0.90
0.007
FOLFIRI 213 4.6
20020408 P + BCS 107 12.3 wks 0.45 0.34–
0.59
p < 0.001
BSC 110 7.3 wks
CO.17 C + BSC 117 3.7 0.4 0.3–0.54 p < 0.001
BSC 113 1.9
RAS mutant
CRYSTAL FOLFIRI + C 246 7.4 1.1 0.85–
1.42
0.47
FOLFIRI 214 7.5
FIRE-3 FOLFIRI + C n.a n.a n.a n.a n.a
FOLFIRI +B n.a n.a
OPUS FOLFOX + C 92 5.6 1.54 1.04–
2.29
0.0309
FOLFOX 75 7.8
PEAK FOLFOX + P n.a n.a n.a n.a n.a
FOLFOX + B n.a n.a
PRIME FOLFOX + P 272 7.3 1.3 1.07–
1.60
p < 0.001
FOLFOX 276 8.7
20050181 FOLFIRI + P 299 4.8 0.86 0.71–
1.05
0.14
FOLFIRI 294 4
20020408 P + BCS 76 7.4 wks 0.99 0.73–
1.36
n.r.
BSC 95 7.3 wks
CO.17 C + BSC 81 1.8 0.99 0.73–
1.35
0.96
BSC 83 1.8
Abbreviations: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; FOL, folinic acid; F, 
fluorouracil; IRI, irinotecan; OX, oxaliplatin; B, bevacizumab; C, cetuximab; P, panitumumab; n.r., not reported; 
BSC, best supportive care.
Table 1. 
Summary of clinical trials and treatment effects within subgroups defined by RAS status in patients with 
metastatic colorectal cancer.
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FOLFIRI in the second-line setting further found no benefit of panitumumab addi-
tion in patients with RAS mutations beyond KRAS exon 2 [35]. Low response rates 
for additional RAS mutations were also reported by a European consortium analyz-
ing tumor samples from a large cohort of patients with chemotherapy-refractory 
mCRC treated with cetuximab and chemotherapy [38].
A systematic review and meta-analysis of nine randomized controlled trials 
for anti-EGFR therapy comprising a total of 5948 participants evaluated for RAS 
mutations has confirmed tumors without any RAS mutations to have significantly 
superior progression-free (PFS) and overall survival (OS) as compared to tumors 
with RAS mutations. No difference in PFS or OS benefit was evident between 
tumors with KRAS exon 2 mutations and tumors with other RAS mutations [33]. 
Treatment guidelines for mCRC now recommend RAS testing prior to start of anti-
EGFR antibody therapy to exclude patients with mutated RAS [2, 21]. However, 
RAS mutations only account for approximately 35–50% of nonresponsive patients, 
and the search for additional biomarkers that predict resistance continues to be an 
active area of research as surveyed below.
2.1.2 Primary tumor location
Colorectal cancers can be broadly grouped by their primary tumor location within 
the colon [39]. The left-sided colon, comprising the distal third of the transverse 
colon, splenic flexure, descending colon, sigmoid colon and rectum, are derived from 
the embryonic hindgut. The right-sided colon, comprising the proximal two-thirds 
of the transverse colon, ascending colon and caecum, is derived from the embryonic 
midgut. Baseline differences exist along the colorectal tract such as cell composi-
tion and function of the epithelium, the microbiome and gene expression. Strong 
evidence for the prognostic effect of primary tumor location is available from clinical 
studies in patients with mCRC, with right-sided tumors exhibiting a worse prognosis 
[40, 41]. Right- and left-sided cancers differ in their clinical and molecular character-
istics: right-sided colon cancers are more likely to be diploid and have high-grade or 
mucinous histology, DNA mismatch-repair deficiency and microsatellite instability, 
CpG island methylation, BRAF, TGFBR2 and PIK3CA mutations [41, 42], while 
left-sided cancers often show chromosome instability, APC, KRAS, SMAD4 and TP53 
mutations [43]. Right-sided tumors have also been associated with more frequent 
overexpression of the EGFR ligands, EREG and AREG, and amplification of EGFR 
and human epidermal growth factor receptor 2 (HER2) [44, 45]. In cohort studies, 
the classification of tumor sidedness is variable, with right-sided tumors commonly 
defined as comprising the region from the ceacum to the splenic flexure.
Clinically, primary tumor location was not considered of particular interest 
in metastatic patients treated with anti-EGFR therapy, until the importance of 
sidedness as a biomarker was recognized. Retrospective surveys of clinical trials 
have indicated that while anti-EGFR therapy provides clinical benefit to patients 
with RAS wild-type mCRC, this benefit is specific to patients with left-sided tumors 
(Table 2). In the CRYSTAL and FIRE-3 studies of cetuximab in the first-line set-
ting, patients with RAS wild-type left-sided tumors had better outcomes compared 
to the respective comparators (FOLFIRI alone and FOLFIRI plus bevacizumab), 
while limited efficacy was observed in patients with RAS wild-type right-sided 
tumors [46]. Benefit from cetuximab treatment specific to patients with KRAS 
wild-type left-sided tumors was further observed for the randomized phase III 
CALGB/SWOG 80405 study of cetuximab or bevacizumab with either irinotecan/5-
FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) [47]. 
Similar results for patients with RAS wild-type left-sided as compared to right-sided 
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tumors were reported for panitumumab for analyses of the PRIME (comparator: 
FOLFOX alone) and PEAK studies (comparator: FOLFOX plus bevacizumab) [48]. 
A meta-analysis integrating these data for the first-line setting is available [49]. For 
the second-line setting, a retrospective analysis of FIRE-3 study also found evidence 
of better outcomes for cetuximab treatment in patients with KRAS wild-type left-
sided tumors as compared to right-sided tumors (comparator: bevacizumab) [50]. 
Similar results for panitumumab were reported in a preliminary efficacy analysis 
of the 20050181 study for RAS/BRAF wild-type patients (comparator FOLFIRI) 
[51]. A retrospective analysis of the CO.17 study in the treatment-refractory set-
ting further observed that only individuals with KRAS wild-type left-sided tumors 
appeared to benefit from cetuximab as compared to BSC [52].
Given the above evidence, NCCN guidelines now recommend the use of anti-
EGFR antibody therapies for the treatment of RAS wild-type left-sided colon 
cancers only [53].
Study Treatment arms Number 
of 
patients
PFS 
(months)
HR 
PFS
95% 
CI
p-Value
Left-sided colorectal cancer
CRYSTAL FOLFIRI 138 8.9 0.5 0.34–
0.72
<0.001
FOLFIRI + C 142 12
PRIME FOLFOX 159 9.2 0.72 0.57–
0.90
n.r.
FOLFOX + P 169 12.9
CALGB/
SWOG 
80405
FOLFOX/FOLFIRI + B 152 11.2 0.84 0.66–
1.06
0.15
FOLFOX/FOLFIRI + C 173 12.7
FIRE-3 FOLFIRI + B 149 10.7 0.9 0.71–
1.14
0.38
FOLFIRI + C 157 10.7
PEAK FOLFOX + P 53 14.6 0.65 0.21–
2.0
n.r.
FOLFOX + B 54 11.5
Right-sided colorectal cancer
CRYSTAL FOLFIRI 51 7.1 0.87 0.47–
1.62
0.66
FOLFIRI + C 33 8.1
PRIME FOLFOX 49 7 0.8 0.50–
1.26
n.r.
FOLFOX + P 39 7.5
CALGB/
SWOG 
80405
FOLFOX/FOLFIRI + B 78 10.2 1.64 1.15–
2.36
0.006
FOLFOX/FOLFIRI + C 71 7.5
FIRE-3 FOLFIRI + B 50 9 1.44 0.92–
2.26
0.11
FOLFIRI + C 38 7.6
PEAK FOLFOX + P 22 8.7 0.84 0.18–
3.79
n.r.
FOLFOX + B 14 12.6
Abbreviations: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; FOL, folinic acid; F, 
fluorouracil; IRI, irinotecan; OX, oxaliplatin; B, bevacizumab; C, cetuximab; P, panitumumab; n.r., not reported; 
BSC, best supportive care.
Table 2. 
Summary of clinical trials and treatment effects within subgroups defined by primary tumor location in 
patients with metastatic colorectal cancer.
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2.2 Future predictive biomarkers for anti-EGFR therapy
2.2.1 Skin toxicity
Dermatological toxicities such as papulopustular rash (acneiform eruption), 
erythema, and skin fissures are common side effects of treatment with anti-EGFR 
antibodies, as EGFR is involved in the normal development and physiology of the 
epidermis [54]. Both undifferentiated and proliferating keratinocytes in the basal 
and suprabasal layers of the epidermis express EGFR, and keratinocytes depend on 
EGFR to regulate proliferation, differentiation, migration, and survival [55]. The 
emergence of skin toxicity has therefore been investigated as an on-target marker 
for anti-EGFR therapy efficacy in patients with mCRC.
Subset analyses of outcomes by skin toxicity severity suggest that improvements 
in outcome are associated with a higher grade of severity for patients treated with 
either panitumumab or cetuximab. For example, in the CRYSTAL trial of cetuximab 
as a first-line therapy, PFS was 11.3 months compared with 5.4 months in patients 
with G3 and G0-1 skin reactions, respectively [56]. Similarly, the randomized phase 
III EPIC study of cetuximab plus irinotecan vs irinotecan after fluoropyrimidine and 
oxaliplatin failure in patients with EGFR-expressing mCRC observed a median PFS of 
15.6 months for patients who developed G3-4 rash compared to 5.8 months for those 
with no rash [57]. In the PRIME study of panitumumab plus FOLFOX4 (first line) and 
20050181 study of panitumumab plus FOLFIRI (second line) the addition of a targeted 
agent even appeared detrimental for outcomes in patients with G0-1 skin toxicity as 
compared to the control arms [58, 59]. Better outcomes in patients with higher-grade 
skin toxicity were further noted for both arms in a randomized trial of cetuximab 
monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic 
colorectal cancer [60]. A meta-analysis by Petrelli et al of 14 studies including a total 
of 3833 patients, found that the occurrence of skin toxicity was a predictive factor for 
survival (HR 0.51; 95% CI 0.40–0.64) and progression (HR 0.58; 95% CI 0.49–0.68). 
However, 12 of the studies included patients with either KRAS wild-type or mutated 
tumors, and data on skin toxicity by KRAS mutation status remains limited.
Analysis of skin toxicity in the randomized phase III ASPECCT study of panitu-
mumab vs cetuximab in chemorefractory wild-type KRAS exon 2 mCRC observed 
improved outcomes in patients with higher grade of severity for both antibodies, 
although patients with higher-grade skin toxicity had longer median duration of 
treatment [61]. Two retrospective trial analyses (PRIME and AIO CRC-0104 [cetux-
imab with CAPOX or CAPIRI, first-line]) suggest that the relationship between skin 
toxicity and outcome may not only apply to patients with wild-type RAS tumors, 
but perhaps also to patients mutant RAS tumors [62, 63]. A recent meta-analysis of 
skin toxicity identified seven and five studies that reported information on PFS and 
OS stratified by KRAS mutation status, respectively [64]. Improved clinical outcome 
in the presence of higher grade severity was observed for both patients with wild-
type KRAS tumors and those with mutant KRAS tumors (PFS for wild-type KRAS, 
HR = 0.60, 95% CI (0.51, 0.70); mutant KRAS, HR = 0.60, 95% CI (0.45, 0.80), OS 
for wild-type KRAS, HR = 0.54, 95% CI (0.46, 0.65), mutant KRAS, HR = 0.64, 95% 
CI (0.50, 0.81), P < 0.001]. However, only mCRC patients with wild-type KRAS 
tumors who suffered grade 2+ skin toxicity derived absolute benefit from anti-EGFR 
treatment additional to best BSC or chemotherapy (PFS HR = 0.58, 95% CI (0.41, 
0.82), OS HR = 0.73, 95% CI (0.61, 0.88)).
These data raise the question whether wild-type RAS patients receiving anti-EGFR 
therapy who do not develop skin toxicity should receive a dose escalation to induce 
skin toxicity or whether treatment should be discontinued. Further prospective data 
are needed to establish the clinical value of skin toxicity as a predictive biomarker.
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2.2.2 EGFR gene copy number
EGFR is localized on chromosome 7p11.2 which exhibits DNA copy number gain 
in approximately 35% of colorectal cancers [65]. Based on this observation, EGFR 
gene copy number has been investigated as a predictive biomarker for anti-EGFR 
therapy in multiple post hoc analyses. Study results have been aggregated in three 
meta-analyses [66-68], which broadly concurred in identifying gain of EGFR gene 
copy number as associated with improved outcomes among patients receiving 
cetuximab or panitumumab treatment. This association was found to be retained in 
subgroup analyses for patients with KRAS wild-type tumors, with one meta- 
analysis suggesting that this difference was not present in patients with KRAS 
mutated tumors [69]. However, the methodologies and criteria used for scoring 
increased EGFR gene copy number were highly inconsistent across different studies, 
and more research is required to clarify the predictive potential of this biomarker.
2.2.3 Amphiregulin (AREG) and epiregulin (EREG) expression
The EGFR ligands AREG and EREG are overexpressed in colorectal cancer at 
both the mRNA and protein levels [70, 71], and suppression of AREG or EREG gene 
expression reduces the therapeutic efficacy of cetuximab in tumor cell lines [72]. 
Accordingly, multiple studies have found evidence that the extent of expression of 
these ligands is related to efficacy of anti-EGFR therapy [71, 73–79].
For example, in the randomized phase III PICCOLO study of panitumumab and 
irinotecan vs irinotecan alone in fluorouracil-resistant mCRC, high messenger RNA 
(mRNA) expression of EREG or AREG (defined as either EREG or AREG in the top 
tertile for mRNA level) was a predictive marker for anti-EGFR therapy benefit in 
patients with wild-type RAS tumors. In contrast, patients with mutant RAS tumors 
gained no panitumumab therapy benefit regardless of ligand status [80]. Similarly, 
in the CO.17 study of cetuximab in chemotherapy-refractory mCRC, wild-type 
KRAS patients with high EREG gene expression obtained benefit from cetuximab 
therapy, while no benefit was observed in patients with low EREG expression; 
patients with mutant KRAS tumors showed no improvement on anti-EGFR 
therapy irrespective of EREG expression levels [76]. A retrospective analysis of the 
single-arm phase II NCT 00508404 study of first-line panitumumab plus FOLFIRI 
similarly also found a higher overall response rate for patients with wild-type RAS 
tumors and high vs low AREG expression [81]. A meta-analysis including eight 
studies that used anti-EGFR therapy alone or in combination with chemotherapy 
reported that AREG/EREG mRNA overexpression was associated with longer 
overall survival in patients with wild-type RAS tumors who received cetuximab or 
panitumumab treatment; AREG overexpression was further associated with longer 
PFS. In contrast, AREG and EREG was found not to have predictive value in patients 
with mutant KRAS tumors [82]. Given these encouraging data, further examination 
of these ligands in prospective controlled trials appears warranted.
2.2.4 BRAF mutation
The BRAF gene encodes a serine-threonine protein kinase that is an integral 
member of the RAS/MAPK signaling pathway. Approximately 10% of colorectal 
cancers harbor activating mutations in BRAF, with a valine (V) to a glutamic acid 
(E) substitution at codon 600 (V600E) accounting for more than 95% of altera-
tions [16]. Mutations in BRAF are mutually exclusive with KRAS mutations in CRC 
[83]. Patients with mCRC who possess a BRAF mutation have significantly poorer 
prognosis as measured by PFS and OS, and mutational analysis is recommended 
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for prognostic stratification in guidelines from the American Society for Clinical 
Pathology, College of American Pathologists, Association for Molecular Pathology, 
and American Society of Clinical Oncology [84]. The relatively low mutation preva-
lence and strong association with prognosis in the metastatic setting have hampered 
conclusive evaluation of BRAF status as a predictive biomarker for anti-EGFR 
therapy in individual trials.
Two meta-analyses of randomized studies of anti-EGFR antibodies have been 
conducted with inconsistent findings. The first meta-analysis of eight randomized 
controlled trials published in seven studies concluded that there was insufficient 
evidence to demonstrate that mCRC patients with wild-type RAS/mutant BRAF 
tumors attain a different treatment benefit from anti-EGFR therapy as compared 
to patients with wild-type RAS/wild-type BRAF tumors [85]. However, the second 
meta-analysis of 10 randomized controlled trials from nine reports focusing on 
wild-type RAS/mutant BRAF tumors reported that anti-EGFR therapy provided 
no benefit in these patients, indicating presence of mutation as a marker of drug 
resistance. Based on these uncertain data, current guidelines for the treatment of 
mCRC do not recommend BRAF mutations as a biomarker for response to anti-
EGFR therapy [84].
2.2.5 PIK3CA mutation
Phosphoinositide 3-kinases (PI3K) are a family of heterodimeric lipid kinases 
which consist of regulatory (p85) and catalytic (p110) subunits. PI3K is a key 
signaling mediator downstream of EGFR involved in the regulation of cell metabo-
lism, growth, proliferation and survival. The PIK3CA gene encodes the catalytic 
subunit, p110α, which, when mutated in cancer, results in constitutively active PI3K 
signaling. PIK3CA mutations are present in approximately 10–20% of colorectal 
cancers, with missense mutations in exon 9 (helical domain) and exon 20 (kinase 
domain) being the most common alterations [86, 87]. Notably, biochemical studies 
comparing mutant p110α proteins have established that exon 9 and exon 20 substi-
tutions have different mechanisms of action. Exon 9-mutant p110α protein induces 
cell transformation independently of binding to p85 but requires interaction with 
RAS-GTP, whereas exon 20-mutant p110α protein is active in the absence of RAS-
GTP binding but is dependent on the interaction with p85 [88].
PIK3CA mutations have been investigated as a potential predictor of anti-EGFR 
therapy efficacy, with studies considering mutation status overall or for exons 9 and 20 
separately. Again, conclusive analyses from individual studies have been hampered by 
the relatively low mutation prevalence, with PIK3CA mutations tending to co-occur 
with KRAS mutations [87]. A series of meta-analyses have been conducted to consoli-
date findings, indicating that PIK3CA mutations as a whole are associated with a lack 
of anti-EGFR therapy response in patients with wild-type RAS tumors [89–93]. Some 
studies further suggest that the predictive power may be confined to exon 20 muta-
tions, although sample size remains limited [90, 91, 94]. However, these meta-analyses 
have included many of the same studies, as well as observed and acknowledged 
between-study heterogeneity. Further investigations are needed before definitive 
conclusions regarding the predictive value of PIK3CA mutations for clinical decision 
making can be drawn, and PIK3CA mutational analysis of colorectal carcinoma tissue 
for therapy selection outside of a clinical trial is currently not recommended [84].
2.2.6 PTEN loss
PTEN is a negative regulator of the PI3K/AKT pathway downstream of 
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in colorectal cancer, with inactivating mutations or loss of protein expression 
observed in approximately 5% and 30% of sporadic colorectal cancers [87, 95, 96].
With respect to response to anti-EGFR therapy, a number of studies have 
indicated an association with PTEN loss and lack of response to cetuximab and 
panitumumab [97–100], although other reports have not identified this relation-
ship [101–103]. There are also data to suggest that some discordance in PTEN 
protein expression may exist between primary tumors and metastases [104]. 
Several meta-analyses have considered published findings, supporting the notion 
that loss of PTEN protein expression and/or mutation are predictive of worse out-
comes in patients with wild-type KRAS tumors treated with anti-EGFR therapy 
[91, 92, 105]. However, given a high level of variability in methods for assessment 
of PTEN expression between studies, including IHC scoring algorithms, and the 
potential inconsistency in expression between primary and metastatic tumor 
samples, loss of PTEN expression cannot yet be regarded as a reliable predic-
tive biomarker. Further investigation and prospective large randomized clinical 
trials are still required to fully confirm the role of PTEN in anti-EGFR therapy 
resistance.
3. Conclusion
The introduction of multiple chemotherapy and biological therapy options 
for the treatment of CRC over the past few decades have driven an increased 
need for predictive biomarkers to select the most appropriate therapy for each 
patient. Biomarker guided treatment selection is critical to improving patient 
outcomes, reducing exposure to ineffective lines of treatment that are associated 
with significant toxicities and costs. For the use of the anti-EGFR antibodies 
cetuximab and panitumumab, current best clinical practice mandates that 
assessment of all common mutations in KRAS and NRAS be undertaken at the 
time of diagnosis of mCRC. Sidedness is also an important factor and it is rec-
ommended to limit anti-EGFR therapy to cases with left-sided primary tumor 
location [53].
Mutations and amplifications of several genes other than RAS have been inves-
tigated as potential predictive biomarkers of response to anti-EGFR therapy. These 
include EGFR gene copy number, BRAF and PIK3CA mutation as well as PTEN 
loss (mutation and loss of protein expression). The individual frequencies of all 
of these mutations and amplifications are low and methodologies to determine 
DNA copy number or protein expression have been highly variable across studies, 
thus whether these alterations are true biomarkers for anti-EGFR therapy resis-
tance remains uncertain. Expression of the EGFR ligands AREG and EREG are an 
interesting avenue to explore, but current evidence is insufficient to recommend 
routine testing in clinical practice. Skin toxicity is a potential predictive marker in 
wild-type RAS patients receiving anti-EGFR therapy, but prospective randomized 
data are required to demonstrate clinical utility and determine how this informa-
tion is best used to inform patient management (dose escalation vs treatment 
discontinuation).
While significant progress has been made in identifying predictive biomarkers 
for anti-EGFR therapy, with RAS mutation status and tumor sidedness endorsed 
as clinical diagnostics, many patients treated with cetuximab and panitumumab as 
selected by these parameters still do not experience treatment benefit. Further basic 
biology and clinical studies are clearly warranted to improve our understanding 
of EGFR signaling to identify novel biomarkers predictive of anti-EGFR therapy 
response and to develop more refined companion diagnostics.
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